Biomolecular Discovery Services
Private Company
Funding information not available
Overview
Biomolecular Discovery Services is a specialized contract research provider founded in 2005, headquartered in Rochester, NY. The company's core expertise lies in phage display-based antibody discovery, offering services ranging from library creation and screening to antibody engineering and affinity maturation. It has developed a strong niche in VHH (nanobody) discovery from both synthetic and immunized camelid sources. As a service-based CRO, its business model is built on providing tailored research solutions to biopharma clients, positioning it in the growing biologics discovery outsourcing market.
Technology Platform
Phage display technology for antibody discovery, specializing in synthetic and immunized VHH (nanobody) libraries, coupled with next-generation sequencing (NGS) analysis.
Opportunities
Risk Factors
Competitive Landscape
Competes in the fragmented antibody discovery CRO market against large, full-service life science CROs and numerous small, specialized firms. Differentiation is based on deep expertise in VHH/phage display, U.S. operations, and NGS integration. Must continually demonstrate value and technical success to retain clients.